
Arcus Biosciences, Inc.
NYSE · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Arcus Biosciences is a clinical-stage biopharmaceutical company that develops small-molecule and antibody-based therapies for cancer, including immunotherapies targeting pathways such as CD73, HIF-2α, and PD-1, often in combination regimens studied through partnerships with larger pharmaceutical companies.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Azoy AlexanderChief Accounting Officer | Sell | $85K | 2,827at $30.00 | Aug 21, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable RCUS activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.